Partner Adam Finerman led a team that included Associates Alexander Davis and Sean Cheatle as they provided legal counsel to Summit Therapeutics Inc. in an agreement whereby AstraZenecamade a $2.0 billion equity investment in Summit through the purchase of convertible preferred shares.
In addition to receiving the equity investment, Summit entered into a clinical collaboration agreement with AstraZeneca to evaluate sonesitatug vedotin (Sone-ve) in combination with ivonescimab with the intent to start studies in certain gastrointestinal (GI) cancer settings imminently. Sone-ve is a potential global first-in-class Claudin 18.2-targeting ADC with several ongoing trials underway in GI cancers. Ivonescimab is a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody.
The transaction closed on Oct. 5, 2026.
